Translations:Atherosclerosis/51/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
FuzzyBot (talk | contribs)
Importing a new version from external source
 
(No difference)

Latest revision as of 22:10, 5 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Atherosclerosis)
Examples of anatomical detection methods include coronary calcium scoring by [[CT scan|CT]], carotid IMT ([[Intima-media thickness|intimal media thickness]]) measurement by ultrasound, and [[intravascular ultrasound]] (IVUS).  Examples of physiologic measurement methods include lipoprotein subclass analysis, [[Glycosylated hemoglobin|HbA1c]], [[C-reactive protein|hs-CRP]], and [[homocysteine]]. Both anatomic and physiologic methods allow early detection before symptoms show up, disease staging, and tracking of disease progression. Anatomic methods are more expensive and some of them are invasive in nature, such as IVUS. On the other hand, physiologic methods are often less expensive and safer. But they do not quantify the current state of the disease or directly track progression. In recent years, developments in [[Nuclear medicine|nuclear imaging]] techniques such as PET and SPECT have provided ways of estimating the severity of atherosclerotic plaques.

Examples of anatomical detection methods include coronary calcium scoring by CT, carotid IMT (intimal media thickness) measurement by ultrasound, and intravascular ultrasound (IVUS). Examples of physiologic measurement methods include lipoprotein subclass analysis, HbA1c, hs-CRP, and homocysteine. Both anatomic and physiologic methods allow early detection before symptoms show up, disease staging, and tracking of disease progression. Anatomic methods are more expensive and some of them are invasive in nature, such as IVUS. On the other hand, physiologic methods are often less expensive and safer. But they do not quantify the current state of the disease or directly track progression. In recent years, developments in nuclear imaging techniques such as PET and SPECT have provided ways of estimating the severity of atherosclerotic plaques.